Online inquiry

IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8699MR)

This product GTTS-WQ8699MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets F3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001178096.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2152
UniProt ID P13726
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8699MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2314MR IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ALXN-1210
GTTS-WQ2551MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 477
GTTS-WQ2873MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG-761
GTTS-WQ13264MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-06252616
GTTS-WQ10150MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LBR-101
GTTS-WQ2471MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 181
GTTS-WQ9549MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA J6M0
GTTS-WQ6152MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CP-675
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW